The carcino-embrionary antigen was estimated in 26 patients without malignant diseases (15 with inguinal hernia and 11 with urinary lithiasis--all of them before surgery), and in 47 patients with urothelial tumors. The direct radioimmune technique was used (a commercial kit from France /CEA IRE SORIN/) applied to isolated samples of sterile urine obtained at 12 hours. It was noted that:--patients without urologic disturbances had values under 1.5 micrograms in 12 hours in 93.4% of the cases;--in 44% of patients with non-malignant urological diseases (urinary lithiasis) the antigen values ranged between 1.5 and 3.0 micrograms in 12 hours;--patients with urothelial tumors had high values of the urinary carcinoembrionary antigen, in the range between 1.92 and 162.5 micrograms;--concentration of the urinary carcino-embionary antigen increases with the stage of the disease, with tumor polyploidia and in tumors with a high degree of anaplasia;--10--14 days after the removal of the tumor the values of the carcino-embrionary antigen show a significant decrease, even after total cystectomy but with cutaneous uretherostomy.

Download full-text PDF

Source

Publication Analysis

Top Keywords

urothelial tumors
12
patients urothelial
8
stage disease
8
carcino-embrionary antigen
8
tumors high
8
antigen
6
[urinary carcinoembryonic
4
carcinoembryonic antigen
4
patients
4
antigen patients
4

Similar Publications

Objectives: To explore the experience of tumor control technique in robot-assisted laparoscopic bladder diverticulectomy (RALBD) in the treatment of bladder diverticulum tumor, intraoperative tumor control and postoperative comprehensive treatment.

Patients And Methods: We treated three male patients with bladder diverticulum tumors. Case 1 involved a 63-year-old with a 3.

View Article and Find Full Text PDF

Introduction: Small cell neuroendocrine carcinoma of the urinary tract (SCNEC-URO) has an inferior prognosis compared to conventional urothelial carcinoma (UC). Here, we evaluate the predictors and patterns of relapse after surgery.

Materials And Methods: We identified a definitive-surgery cohort (n = 224) from an institutional database of patients with cT1-T4NxM0 SCNEC-URO treated in 1985-2021.

View Article and Find Full Text PDF

Bladder cancer remains a significant global health concern, being the 10th most common malignancy worldwide and the 6th most common neoplasia in males, with alarming annual incidence and mortality rates. The current narrative review was planned to delve into the multifaceted landscape of bladder cancer, exploring its epidemiology, risk factors and diagnostic modalities. While white light cystoscopy has long been considered the gold standard for bladder cancer diagnosis and surveillance, the emergence of blue light cystoscopy has ushered in a new era of early detection.

View Article and Find Full Text PDF

(Purpose) Enfortumab vedotin has been available as a third-line treatment for advanced urothelial carcinoma in Japan since December 2021. While the treatment is expected to improve the outcome of advanced urothelial carcinoma, concerns regarding adverse events do exist. We report here our initial experience of the use of enfortumab vedotin as a third-line therapy in patients with advanced urothelial carcinoma.

View Article and Find Full Text PDF

(Purpose) We performed a clinical retrospective study on the evaluation of pembrolizumab treatment results for advanced urothelial cancer in our hospital. (Materials and Methods) Twenty-seven patients diagnosed with advanced or metastatic urothelial carcinoma who received pembrolizumab between April 2018 and December 2021 were included. We retrospectively reviewed medical records to examine treatment outcomes, immune-related adverse event (irAE), and prognostic factors.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!